A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests
Authors
Keywords
-
Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 14, Issue 5, Pages 517-524
Publisher
Informa UK Limited
Online
2014-05-21
DOI
10.1586/14737159.2014.910120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial
- (2014) Susana Benlloch et al. PLoS One
- Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer
- (2013) Patrick O’Donnell et al. BMC CANCER
- Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers
- (2013) E. Conde et al. Clinical & Translational Oncology
- Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
- (2013) D Gonzalez de Castro et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of 2 Real-Time PCR Assays for In Vitro Diagnostic Use in the Rapid and Multiplex Detection of EGFR Gene Mutations in NSCLC
- (2013) Anthony T.C. Wong et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Comparison of molecular testing methods for the detection ofEGFRmutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
- (2013) Fernando Lopez-Rios et al. JOURNAL OF CLINICAL PATHOLOGY
- Detection of BRAF V600 Mutations in Metastatic Melanoma
- (2013) Kevin Qu et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
- (2013) Fernando Lopez-Rios et al. PLoS One
- Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas
- (2013) Alexandre Harlé et al. VIRCHOWS ARCHIV
- Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma
- (2012) Steven Anderson et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
- (2012) D Gonzalez de Castro et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas
- (2012) Johanne Lade-Keller et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Chipping away at the lung cancer genome
- (2012) William Pao et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment implications of the emerging molecular classification system for melanoma
- (2011) Emanuela Romano et al. LANCET ONCOLOGY
- Cancer genomics: from discovery science to personalized medicine
- (2011) Lynda Chin et al. NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
- (2011) Sung Lee et al. VIRCHOWS ARCHIV
- A standardized framework for the validation and verification of clinical molecular genetic tests
- (2010) Christopher J Mattocks et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- (2009) Helena Linardou et al. Nature Reviews Clinical Oncology
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine
- (2008) Paul Workman et al. CURRENT OPINION IN PHARMACOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More